Trial Profile
A Phase I, Double-Blind, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX320 and IDX184 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs IDX 184 (Primary) ; IDX 320 (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 16 Aug 2012 The US FDA has placed a partial clinical hold on IDX 184, according to a Idenix Pharmaceuticals media release.
- 07 Sep 2010 Full data will be presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) 2010, according to an Idenix media release.
- 07 Sep 2010 Status changed from recruiting to completed, according to an Idenix media release.